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How will the coronavirus disease 2019 (COVID-19) pandemic develop in the coming months and years?
Based on an expert survey, we examine key aspects that are likely to influence the COVID-19 pandemic in
Europe. The challenges and developments will strongly depend on the progress of national and global vacci-
nation programs, the emergence and spread of variants of concern (VOCs), and public responses to non-phar-
maceutical interventions (NPIs). In the short term, many people remain unvaccinated, VOCs continue to
emerge and spread, and mobility and population mixing are expected to increase. Therefore, lifting restric-
tions too much and too early risk another damaging wave. This challenge remains despite the reduced oppor-
tunities for transmission given vaccination progress and reduced indoor mixing in summer 2021. In autumnCOVID-19
SARS-CoV-2
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2 E.N. Iftekhar et al. / The Lancet Regional Health - Europe 00 (2021) 1001852021, increased indoor activity might accelerate the spread again, whilst a necessary reintroduction of NPIs
might be too slow. The incidence may strongly rise again, possibly filling intensive care units, if vaccination
levels are not high enough. A moderate, adaptive level of NPIs will thus remain necessary. These epidemio-
logical aspects combined with economic, social, and health-related consequences provide a more holistic
perspective on the future of the COVID-19 pandemic.







More than a year after the World Health Organization declared
the coronavirus disease 2019 (COVID-19) a Public Health Emergency
of International Concern, Europe continues to struggle with it.
Although future developments are highly uncertain, we aim to pro-
vide (a) a systematic assessment of the factors that will affect the
course of the COVID-19 pandemic in Europe, and (b) a tentative fore-
cast of how the pandemic may evolve prior to coming to an end in
Europe. We chose a method inspired by the Delphi method of fore-
casting [1] as the most suitable way to elicit expert opinions about
key developments and themes regarding the COVID-19 pandemic.
The facilitators developed questionnaires with open-ended questions
and asked scientists from various European countries, disciplines,
and research fields, to provide their input and predictions. As the
guiding questionnaires were focussed on epidemiology, virology,
public health, and social science, some other important perspectives,
such as those of clinical medicine, economics, and the humanities,
are not covered in great detail (see SI). Here we set out the results of
the expert consultation—outlining salient commonalities and diver-
gent responses. Of necessity, this paper represents a partial synthesis
of the rich and diverse contributions, and not all authors necessarily
agree in detail with every single statement.
We first summarize insights on three critical factors that shape
the development of the epidemic: population immunity and vaccina-
tion, variants of concern (VOCs), and public responses to pandemic
policy. Second, we present scenarios based on the available knowl-
edge as of April 2021 for three distinct time periods: for (a) summer
2021, (b) autumn and winter 2021, and (c) for a period of 35 years
from spring 2021. For the latter period, we give a high-level overview
of the consequences of the COVID-19 pandemic for health, society,
and the economy. In the last section, we elaborate in more detail on
central topics mentioned in the main text: long-term strategy, vacci-
nation coverage, organization of mass vaccinations, waning immu-
nity, evolution of the virus, improving adherence, airborne
transmission, and One Health. We hope that the insights of our syn-
thesis will serve as a scientific basis for policy debates by generating
a comprehensive overview of key considerations in moving beyond
the pandemic, while informing other foresight studies.2. Key factors determining the course of the pandemic
Our starting point is the situation as of spring 2021. During the
COVID-19 waves in winter 20202021, many European countries
experienced high numbers of infections that, in some places, over-
whelmed hospitals. This was partly due to insufficient ICU capacity in
some countries [2]. Delayed responses and lower effectiveness of
non-pharmaceutical interventions (NPIs) compared to the first wave
also played a part [3]. Even countries that have had relatively few
cases and a low death toll until then were hit severely in the winter.
As of early 2021, Europe is experiencing another surge in cases,
which appears to have peaked in April 2021. The emergence and
severity of these waves has varied greatly across Europe (see Figs. 1
and 2). The future development of the pandemic will also likely be
heterogeneous. In the following sections we focus on three key fac-
tors that contribute to this heterogeneity., A look into the future of th
org/10.1016/j.lanepe.2021.102.1. Population immunity and vaccination
Population immunity (also referred to as herd immunity)
describes a situation in which enough people in the population are
immune to a pathogen, such that it is not able to spread widely
(WHO, 2020a). The proportion of immune people in the population
needed to reach population immunity in a given country is mainly
driven by the infectivity of severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) and the ability of either past natural infection
or vaccines to reduce transmission [4]. Models that assume basic
reproduction numbers of 2535 have previously estimated that
transmission-blocking immunity of 6072% of the population is
required in the case of SARS-CoV-2 [5,6]. This figure is higher for
more transmissible variants. Therefore a minimum immunization
level of 80% of the entire population is likely to be required [7,8]. This
figure would be difficult to achieve with vaccination alone if vaccines
are not fully protective against infection or prevent onward transmis-
sion. Furthermore, immunization needs to be homogeneous across all
population groups, otherwise pockets of transmission can prevail. To
achieve this goal, one might consider mandatory vaccinations - the
effectiveness of which remains contested, as vaccination uptake
depends on a complex interplay of different factors [9,10]. A 2016
systematic review found that mandatory childhood vaccination poli-
cies were associated with improved uptake [11], a finding supported
by later experience in Italy [12,13]. However, there are many legal,
ethical, cultural, and technical issues involved and it has been argued
that it should only be considered when all other reasons for low
uptake, such as accessibility, have been addressed and the decision
should take account of the particular context and the risk of unin-
tended consequences [9,14-17]. In any case, for the short term it is
more important to distribute available vaccines to locations where
they are most needed [18].
One contribution to population immunity comes from so-called
natural immunity, as a result of prior infection with SARS-CoV-2 and
potentially by cross-immunity due to prior exposure to other corona-
viruses [19,20]. The fraction of those who are naturally immune in
the population varies widely between European countries. However,
in all countries the majority of the population remained susceptible
to infection [21].
In individuals who have had a SARS-CoV-2 infection, antibodies
have been shown to persist for up to nine months after infection [22].
About 95% of people retain immune memory at six months after
infection [23-25]. This indicates that the likelihood of reinfection and
severe disease progression is low in this time frame, but reinfection
is still possible [26-28].
The second, major, contributor to population immunity is vaccina-
tion. The first vaccines are, as of April 2021, licensed for use in adults
and the vaccines appear to reduce infections by varying amounts,
typically in the 8090% range for mRNA vaccines (after two doses)
[29-31] and potentially lower for others [32,33]. Vaccines are, how-
ever, still likely to reduce transmissibility even if breakthrough infec-
tion occurs [34]. Importantly, they seem especially likely to prevent
severe symptoms and hospitalization, reaching relative risk reduc-
tions of about 7095% [30,32,35-37]. The progress of vaccination pro-
grams is continuing in Europe (see Fig. 3) [38].
The chances of achieving high vaccination coverage depend on a
multitude of factors including political leadership, trust in publice COVID-19 pandemic in Europe: an expert consultation, The Lancet
0185
Fig. 1. Comparison of the COVID-19 pandemic in all countries of the WHO European Region (except for Turkey and Turkmenistan, as there was no appropriate data available in the
data set). Countries are ordered from top to bottom with a decreasing cumulative number of COVID-19 related deaths per million people. The y-axis scale of the ridgeline plots is
the same for all countries for reported deaths and incidence, respectively. Even though reported numbers are associated with wide uncertainty, the differences between countries
and waves are evident. Data source: https://corona-api.com (Accessed: June 28, 2021).
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cines, and vaccine acceptance. The last is especially crucial. As of April
2021, acceptance is lower for the non-mRNA-vaccines with lower
reported efficacies. Repeatedly changing policy recommendations
and constant media coverage further unsettled people, especially
after evidence of possible links to rare adverse, sometimes fatal, side-
effects emerged mid-rollout for the AZD1222 (AstraZeneca) and
Ad26.COV2.S (Johnson & Johnson) vaccines [39,40]. Among older
people and the most vulnerable, who have been receiving the vaccine
in the initial phase, vaccine uptake has been generally high [41,42]. In
younger age groups, willingness to get vaccinated appears lower
[43,44]—in France, only about 40% of the working age population cur-
rently plan to accept a vaccine [45]. Moreover, vaccine uptake in the
groups of healthcare workers is rather disconcerting in some coun-
tries—e.g., Belgium and France—has been low [46-48]. However, per-
ception of increasing vaccine uptake might motivate those who are
hesitant [49]. To conclude, the issue of vaccine uptake presents an
ever-changing situation [50].
2.2. Variants of concern
VOCs are so called because they harbour certain mutations that
have consequences for SARS-CoV-2 pathogenicity. Existing and
newly emerging SARS-CoV-2 VOCs are challenging because,Please cite this article as: E.N. Iftekhar et al., A look into the future of the
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10compared to the original variant, they may increase transmissibility
or severity, prolong the duration of the infectious period, shorten the
duration of post-infection immunity, or escape host immune
responses to natural infection or to vaccines. They could also affect
diagnostic testing accuracy, the spectrum of detectable symptoms,
and therapeutic management. The frequency and the spectrum of
variants of SARS-CoV-2 will depend on functional constraints and
evolutionary pressure.
The Alpha (B.1.1.7) variant, which was first detected in the
United Kingdom, demonstrated enhanced transmissibility [51,52], a
longer duration of acute infection [53], a higher hospitalization rate
[54], and probably a higher infection fatality rate than previously
circulating variants [51,55-57]. The Beta (B.1.351) variant, which
was first detected in South Africa, exhibits higher transmissibility
[58], while the impact on disease severity of this variant remains
uncertain as of April 2021 [59]. The Beta and Gamma (P.1) variants,
the latter originated in Brazil, seem to partially evade the immune
response of previously infected individuals [26,60]. In Europe, the
Alpha variant became the dominant variant in December/January
2020 in, e.g., the UK, Ireland and Portugal, and in February/March
2021 in, e.g., France and Germany [61]. In contrast, the Beta and
Gamma variants have not become widely distributed in Europe so
far. The Delta (B.1.617.2) variant appears to be more transmissible
than previous strains [62].COVID-19 pandemic in Europe: an expert consultation, The Lancet
0185
Fig. 2. Comparison of the COVID-19 pandemic in a selection of European countries grouped by geographical proximity. Many differences in reported incidence, reported deaths and
excess mortality can be observed. Even though reported numbers are associated with wide uncertainty, the differences between countries and waves are evident. Data sources:
https://ourworldindata.org/covid-cases and https://ourworldindata.org/excess-mortality-covid (Accessed: June 29, 2021).
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relation to VOCs. Current vaccines appear to be effective against
Alpha [29,31]. However, there is some evidence that the efficacy of
some vaccines might be reduced for Beta, Gamma, and Delta [32,62-
64]. It remains unclear to which degree this is the case, and how
much the protection against severe courses of disease might be
affected.
The more infections are present in the human population, the
higher the rate of mutation. This can lead to selection for VOCs with
transmission advantage or, in places with high rates of natural or vac-
cinal immunity, VOCs with escape mutations. In countries without
well established genetic surveillance, this may permit uncontrolled
spread. In this case, vaccines will need to be updated to protect
against these new VOCs, with the consequent requirements to gain
approval, be manufactured, and distributed anew. However, the
more widespread infections are, the more mutations will occur that
could end up with an evolutionary advantage. Consequently, the best
safeguard is to reduce transmission. Only after sufficient global vacci-
nation coverage will the mutation rate decrease due to lower viral
spread in the post-pandemic phase [8].2.3. Public responses to pandemic policy
As long as population immunity has not been reached, maintain-
ing appropriate and widely accepted levels of NPIs to mitigate the
spread remains crucial [65,66]. When there is a rise in infections,
NPIs must be reimplemented or strengthened; the earlier this is
done, the more effective it is [67]. However, the resoluteness and
timeliness with which NPIs are being implemented and remain in
place depends on leadership and public opinion [68]. Moreover, thePlease cite this article as: E.N. Iftekhar et al., A look into the future of th
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10higher the efficacy of NPIs the more the public accept and support
them [69].
As of spring 2021, pandemic policies are not being received well
in many parts of Europe [70]. A range of factors likely contribute to
this, including continued high economic [71-73] and psychological
burdens [74-79], inadequate risk communication [80-83], the lack of
transparent long-term strategies from governments [68], increasing
vaccination coverage (see Fig. 3) and a general erosion of trust [84-
88]. All this results in lower adherence to rules and recommendations
for mitigating the spread of SARS-CoV-2 compared to the first wave
[70,89].
The effectiveness of rules and recommendations depends on the
ability and willingness of the population to adhere to them [81].
Adherence in the past year has varied from country to country. In
some countries, adherence was initially quite high in general [89-93].
In others, there have been strong protests against measures, some-
times resulting in their relaxation [94-96]. In general, voluntary
adherence will be more likely if the necessity for and strategy behind
instituted measures is communicated clearly and systematically, and
if interpersonal trust and public trust in government is higher [70,97-
100]. However, if COVID-19-induced morbidity and mortality reaches
levels that societies deem intolerable, acceptance of NPIs rises again
[70]
Given these key factors underlying the future evolution of the
pandemic, we can consider what to expect in the future, beginning
with the summer of 2021.
3. The perspective for the summer of 2021
Summer 2021 is likely to bring some relief in Europe as people
spend more time outside [101], vaccination proceeds, and controle COVID-19 pandemic in Europe: an expert consultation, The Lancet
0185
Fig. 3. Vaccination progress in Europe. a. Fraction of the population having received at least one dose of COVID-19 vaccines in Europe as of June 26, 2021. There are large differences
in vaccination coverage. b. Reported incidence (lines) and reached vaccination milestones (triangles) since the start of vaccination programs. Data source: https://ourworldindata.
org/covid-vaccinations (Accessed: June 29, 2021).
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ing technology [102]. The expected relief might be compromised if
the combination of natural immunity and vaccination coverage is
low and relaxation of NPIs is not managed carefully. Furthermore,
increased international travel will increase the risk of importing any
VOCs that emerge from outside of Europe, and the risk of circulating
any VOCs that emerge from within the continent across European
nations. If VOCs with an ability to evade immune responses emerge,
NPIs may need to be reinstated or strengthened even in populations
where relatively high levels of immunity have been achieved. A com-
mon European goal to keep infection levels low and to internationally
coordinate close surveillance of incidence and viral genomes, espe-
cially of infected international travelers, would help to reduce the
risk of emergence of VOCs [103].
Once vaccination coverage is deemed sufficiently high by decision
makers, countries might come under further pressure to ease meas-
ures again. With (most) risk groups vaccinated first, there will be a
lower fraction of severe illnesses and deaths related to COVID-19 in
the population. Consequently, a lower burden on healthcare systems
is also expected. However, some individuals at risk might not (yet)
have been vaccinated, protection by vaccination is not perfect and
may wane over time, and unvaccinated and possibly some vaccinated
people will continue to transmit. This makes it unlikely that restric-
tions can be lifted completely without risking another larger wave.
Another wave would result in increased morbidity and mortality of
unvaccinated people, or in general those to whom the vaccines did
not confer protection [104]. With vaccine strategies first targeting
older people, a wave in summer would predominantly hit relatively
younger age groups. It would also further strain exhausted healthcare
personnel and healthcare systems now functioning beyond capacity
for protracted periods of time. Hence, certain mitigation strategies
will need to remain in place in an adaptive manner [105]. When con-
sidering retaining NPIs, countries might also take the opportunity to
achieve low case numbers as, with increasing immunization, the con-
tainment of COVID-19 is facilitated. In a situation of low case num-
bers, an effective test-trace-and-isolate (TTI) system, supported by
digital contact tracing apps, further facilitates epidemic control [106].
In such a regime, only a few NPIs, such as wearing (FFP2) masks or
basic hygiene measures, might have to stay in place.
To summarise, in the summer of 2021, countries could still be
faced with overwhelmed intensive care units and ongoing strict
imposition of NPIs. This is a consequence of the limits of the vaccines
available, inadequate vaccination coverage, increased mobility across
borders and regions, and the possibility of escape variants. However,
if a country succeeds in maintaining low case numbers and slowsPlease cite this article as: E.N. Iftekhar et al., A look into the future of the
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10down the influx and spread of any new VOC with sound epidemiolog-
ical surveillance and reactive measures, then moderately strict NPIs
similar to those in summer 2020, or potentially even fewer restric-
tions, may be possible. The exact extent of NPIs that are necessary to
prevent an overburdening of health systems regionally depends on
various factors, such as the characteristics of prevalent VOCs and vac-
cination coverage. A full lifting of all restrictions (e.g., for large indoor
gatherings), however, is unlikely to be possible in summer 2021
without risking further outbreaks.4. The perspective for the autumn and winter of 2021
What can be expected in the autumn and winter of 2021 depends
substantially on what happens in the summer; specifically, the suc-
cess of vaccination programs both in Europe and worldwide, and the
emergence and spread of (new) VOCs. Compared to the summer,
autumn and winter bring the additional complication of unfavorable
seasonal effects.
The seasonality of coronaviruses is expected to increase infections
in the autumn and winter months [101,107,108], with increased
indoor contacts [109]. Additionally, other seasonal viruses, such as
influenza and respiratory syncytial virus, could cause more pressure
on health services than in 2020. Since there might be fewer restric-
tions, and possibly lower-than-usual levels of population immunity
because one season of transmission was “skipped”, these other sea-
sonal viruses are likely to circulate in greater numbers than in 2020
[110,111]. Overall, the transition to autumn and winter could be
problematic because restrictions might have to be tightened again to
prevent a rapid rise in case numbers. Based on experiences in several
European states in autumn and winter 2020-2021, there is a risk that
reintroduction of the necessary public health measures may come
too late to succeed in preventing another wave in autumn. It will be
the task of governments not to repeat these mistakes.
In the best-case scenario, vaccination efforts will have been suffi-
cient to drive down case and fatality numbers substantially, allowing
for an almost complete lifting of restrictions. Although vaccination of
children aged 12 years and over might have started by this point
[112], other groups which have yet to be vaccinated might still suffer
from relatively high incidence rates. As the oldest and most vulnera-
ble population groups at highest risk of death from COVID-19 have
been prioritised for vaccination, the overall fatality rate in the popu-
lation and the health burden imposed by SARS-CoV-2 will decline.
Hence, the perception of the remaining danger might be low: more
than 10% of infected individuals are expected to suffer long-termCOVID-19 pandemic in Europe: an expert consultation, The Lancet
0185
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include shortness of breath, fatigue, and muscle weakness [113-117].
Assuming increased international mobility due to, in particular,
high vaccination coverage, a potential outbreak of a new VOC in one
country may spread quickly to others. Without rapid intervention,
increased mobility may result in simultaneous outbreaks across
countries and regions - potentially putting healthcare systems under
high pressure. In light of this danger, a joint effort of all European
countries to prevent the emergence and circulation of VOCs seems
crucial [118,119].
In short, countries with good access to vaccines and high vaccine
uptake can, at worst, expect only modest waves of COVID-19 over
the winter when maintaining moderate NPIs (e.g. no large indoor
gatherings, face masks, physical distancing, good ventilation, and
hygiene). In contrast, countries that have a lower level of vaccination
coverage will experience more severe waves unless appropriate NPIs
are implemented. Any new VOCs might challenge a successful mitiga-
tion or containment strategy, and in case of increased mobility, they
are likely to spread quickly.
5. The perspective for the coming 35 years
For the coming three to five years, the central questions are: Will
we leave the pandemic behind? And if we do—when and how? To
what degree will COVID-19 continue to play a role? Regarding the
direct health impact of COVID-19, it is possible that it could become a
disease that a child will encounter at a young age [120], acquiring a
mild infection similar to contracting other coronaviruses. The time
scale for this shift is uncertain. Early childhood exposure and recov-
ery may help the immune system to protect the individual, should
they encounter the virus again later in life, and should prevent them
from experiencing severe symptoms. On the other hand, SARS-CoV-2
(and more so new VOCs) is more infectious and lethal than the
known endemic human coronaviruses, and there is the continued
risk of long-COVID. Similarities to Chikungunya suggest that long-
COVID may become a great burden [121]. However, relief might
come from new and improved post-exposure therapeutic options,
such as antiviral medication and monoclonal antibodies [122]. Hence,
there is mixed evidence whether SARS-CoV-2 will remain a serious
threat to health in the long-term.
It is unclear whether eradication of SARS-CoV-2, i.e., a global
reduction to zero incidence of infection [123], can be achieved. Global
mass vaccination programs might only provide imperfect immunity
to some individuals and will usually not reach certain subpopula-
tions, leaving pockets of susceptibility. Transmissions within these
subpopulations, the high proportion of asymptomatic COVID-19
infections, and waning of post-infection and vaccine-induced immu-
nity could maintain the circulation of the virus in the global popula-
tion. Even if eliminated in humans, the multitude of documented
non-human hosts [124-127] suggest the virus could remain circulat-
ing with ongoing risks of infection of and potential further spread
between susceptible human hosts. Furthermore, the virus could
mutate within human or non-human hosts to escape immune
response, potentially requiring repeated booster vaccinations. In any
case, eradicating SARS-CoV-2 would require global political commit-
ment and unified and uniform public assent that eradication is the
overarching target. With the smallpox virus, the only virus able to
infect humans to have been eradicated, a targeted and globally con-
certed approach over decades was necessary [128,129], with a partic-
ular focus also on reaching deprived populations [130].
Elimination, meaning here a temporary reduction to zero inci-
dence of infection in one region or country through deliberate and
continued measures, has been achieved in a small number of coun-
tries; e.g., Australia, China, New Zealand, Singapore, and Vietnam.
With widespread vaccination, others may try to follow as elimination
strategies can offer advantages over mitigation or suppressionPlease cite this article as: E.N. Iftekhar et al., A look into the future of th
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10strategies with continued virus circulation [131]. Assuming that chil-
dren will also be vaccinated, some of these countries might achieve
high enough vaccine uptake to sustainably prevent local transmis-
sion. In other countries where immunity in the population is insuffi-
cient or too heterogeneous for elimination, SARS-CoV-2 is expected
to remain prevalent at a comparatively low level, with recurring local
and seasonal outbreaks [120,132]. In the absence of eradication, epi-
demiological surveillance (and TTI) will need to remain in place and
be further improved [53]. The level of immunity in the population
will prevent widespread morbidity and mortality, but a significant
danger might remain for unvaccinated vulnerable people [4]. A key
societal question will be which level of such risk is deemed accept-
able when balancing other societal goals.
Finally, Europe faces numerous indirect long-term impacts of the
pandemic. Without intending to present a complete list, the conse-
quences include:
Health: During the past year there has been a direct impact on
healthcare services in regular care, particularly for patients with
chronic conditions [133-135]. This includes reduced access to pri-
mary care [136], cancellation of elective medical and surgical pro-
cedures [137], and disruptions to screening programs [138,139].
Potential suboptimal healthcare provision for non-communicable
diseases might cause a progression of chronic diseases and compli-
cations of acute diseases. At-risk populations not sufficiently cov-
ered by screening programs might now develop serious disease
within a 3- to 5-year period. Hence, further health- and economic
burdens (increased sick days, decreased workforce, lost productiv-
ity, and increased healthcare costs) might be experienced by some
countries due to the rise in the prevalence of non-communicable
diseases [140]. With potentially increasing investment into pan-
demic preparedness, there is a risk of cuts in other public health
sectors, aggravating the effects on prevention and chronic disease
control. Additionally, the enormous consequences for mental
health during this pandemic, especially in young people [75,79],
healthcare workers [141], and individuals already suffering from
social disadvantage and discrimination [142-145], will have a pro-
tracted effect. Whilst the consequences do not appear to extend to
higher suicide rates [146], there is the need to redirect services
and ensure sound mental health and social care support to the
population.
Economy: Although many facets of the economy in some wealthy
countries may soon recover [71], others will struggle to overcome
the economic crisis. The tourism industry has suffered gravely,
endangering livelihoods and economies in countries that depend on
it; and driving a widening divide between Northern and Southern
Europe [147]. The cultural sector has also been hit economically by
the pandemic [148-151]. Public debt has been growing, and this
poses a risk to financial stability - especially in countries more
strongly hit by the pandemic. Increasing digitalization, and remote
and flexible work plans, will potentially change employment [152].
Meanwhile, the legislative and regulatory frameworks for these new
forms of work, along with supporting mechanisms (e.g., for sound
occupational health), are lagging behind.
Society: Inequalities have been exacerbated because of this pan-
demic [144,153,154]. This extends well beyond health inequalities
[155] to gender [156,157] and educational [158] inequalities. Many
children have missed out on extended periods of face-to-face educa-
tion, as well as general social interaction. At the same time, there has
been further erosion of trust between citizens and states through a
widening of the socioeconomic gap [145,159-161]. These two factors
present a threat to social cohesion and might cause social unrest in
the years to come. Furthermore, the narrative of “outside threats”
and “secure borders” in discussions about the virus might contribute
to the intensification of pre-existing nationalistic and sometimes
overtly xenophobic, social and political discourses [162]. The weak-
ened cultural sector might further be challenged by long-lastinge COVID-19 pandemic in Europe: an expert consultation, The Lancet
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ties could approach and engage with these issues. Moreover, a lot of
progress on the Sustainable Development Goals, in particular on pov-
erty reduction, will be reversed [163].
Even if the rate of new infections eventually significantly
decreases, the health-related, economic and social damages of the
pandemic will be felt for a long time.
6. The way forward
We can conclude that COVID-19 will continue to pose many chal-
lenges over the coming years. The economic, cultural, and health con-
sequences of the pandemic are already immense and societies may
need a long time to recover. The increasing availability of vaccines
will bring significant relief over the next months, but if not accompa-
nied with comprehensive strategies and public support they alone
will not protect from further damaging outbreaks in the coming
years. Limited uptake of vaccines and declining public adherence to
NPIs impede the way out of the pandemic and in the worst case new
VOCs can render current vaccines less effective.
The eradication, i.e. the complete global elimination, of SARS-CoV-
2 seems unlikely. However, even if eradication cannot be achieved,
strategies that aim to locally eliminate SARS-CoV-2 might be effective
in some settings. If achieved, local elimination offers clear advantages
over mitigation or suppression with continued virus circulation, at
least until sufficient protection against severe symptoms is granted
in the population. A successful strategy for elimination or suppres-
sion of SARS-CoV-2 would require a political commitment, unified
and uniform public assent that elimination or the goal of low case
numbers is the overarching target. To achieve said target, a clear, evi-
dence-informed, and context-relevant strategy, as well as concerted
efforts and actioning are crucial. Countries committing to that strat-
egy would need to have (a) rapid vaccination programs across age
groups, (b) sufficient NPIs that may only be lifted if the susceptible
population at risk is small, (c) close communication between policy-
makers and a wide range of experts to weigh the societal costs and
benefits of measures against each other, (d) mitigation of virus influx
from regions with higher incidence, and (e) sufficient public health
infrastructure. This infrastructure entails basic public health resour-
ces, well-trained personnel of sufficient number, well-functioning
TTI systems, widespread sequencing of the virus variants, and well-
established molecular surveillance mechanisms. International coordi-
nation and cooperation on all these points and on continued develop-
ment of new drugs and vaccines (also for potential new VOCs) is
essential.
In line with the Sustainable Development Goals, healthy lives
should be a global common good and initiatives like COVID-19 Vac-
cines Global Access (COVAX) should receive more support. Support of
low- and middle-income countries by high-income countries is not
only crucial to mitigate VOCs, but is mandated by the principle of sol-
idarity [103,164,165]. In the long-term, a global One Health approach
to pandemic preparedness and control is crucial - respecting the
interdependence of humans, animals, and the environment [166].
7. Discussion of parameters, strategies and their context
The following presents more detailed elaborations of some of the
aspects discussed in the preceeding sections and a summary of
important additional topics. For a more comprehensive narrative in
each of these sections there is, inevitably, some overlap with previous
text.
7.1. Long-term strategy
To minimize the damage caused by the COVID-19 pandemic, a
long-term strategy set on a common, global and overarching goal isPlease cite this article as: E.N. Iftekhar et al., A look into the future of the
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10required. By communicating a common goal that societies are work-
ing towards and by clearly formulating the reasoning behind the
implementation of measures, they will be perceived as less arbitrary
[77]. Such a strategy must be comprehensible and based on scientific
evidence not only from epidemiology, but from a wide range of disci-
plines. Communication between politicians and experts for transpar-
ent, evidence-informed policymaking and comprehensive
systematically updated context-relevant risk communication strate-
gies is crucial. However, to be comprehensible a strategy also needs
consistent concepts that are perceived as both understandable and
fair. Hence, and vitally, any strategy needs to be underpinned by con-
siderations of justice and (global) inequalities. The more comprehen-
sible and fairer such models of pandemic management are, the more
people will be willing to support more extensive interventions in
their everyday life [83]. This also includes showing that not all popu-
lation groups are affected by the pandemic in the same way.
Specifics of the strategy will necessarily vary locally and also
change over time in the face of more data about (a) the virus, particu-
larly current and newly-emerging VOCs, (b) the development of vac-
cines and treatments, and (c) the harms accrued to individuals,
communities, and societies through restrictions. Any strategy needs
to balance the damage of being harmed by the virus against the dam-
age by the measures to contain it. This will shift in response to the
vaccination progress. Thus, it would be problematic if governments
became fixed upon a specific strategy and remained committed to it
regardless of new evidence and circumstances.
Any strategy should not simply be developed by politicians and
imposed on the public: such impactful strategies should, as far as
possible, be based on societal consensus, although recognising that
some politicians may base their views purely on ideological premises.
Moreover, measures are much more likely to be successful if they are
developed through a process of co-production with those who must
implement them and who are most affected [167].
7.2. Vaccination coverage
7.2.1. When will sufficient vaccination coverage be reached?
Vaccination programs are progressing in Europe (see Fig. 3) [38].
The chances of achieving high vaccination coverage depend on politi-
cal leadership, access to vaccines and concerns and anxieties in rela-
tion to vaccination [168]. The latter especially differs from country to
country [169]. At present, with mostly the eldest and most vulnerable
receiving the vaccine, vaccine uptake has been generally high [41,42].
In the younger groups, willingness to be vaccinated is lower [43,44],
limiting the final average uptake. In some countries, only about 40%
of the adult population currently plan to accept the offer of vaccina-
tion [45]. Moreover, it is concerning that, in some countries, there is
significant vaccine hesitancy among healthcare workers [46,47].
However, perception of increasing vaccine uptake might motivate
those who are hesitant [49].
If the aim is to reach population immunity, children will have to
be vaccinated as well, because the required level of immunization for
population immunity likely cannot be reached otherwise. If not
immunized, infections in children might become central for an
annual autumn or winter epidemic. High incidence in children also
poses the risk that the virus may spread to vulnerable individuals in
the general population with waning immunity. Children are likely to
become eligible for vaccination in 2021 [112]. However, parental per-
spectives on and ethical considerations around childhood vaccination
may pose significant challenges [170].
As of April 2021, vaccination programs in many countries have
slowed down. Repeatedly changing policy recommendations and
constant media coverage seem to have unsettled many people, after
evidence of rare adverse, sometimes fatal, side-effects emerged mid-
rollout for the AZD1222 (AstraZeneca) and Ad26.COV2.S (Johnson &
Johnson) vaccines [39,40]. Likely because of this, some people ratherCOVID-19 pandemic in Europe: an expert consultation, The Lancet
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vaccination coverage and successful control of the pandemic may
decrease the willingness to get vaccinated at all because the per-
ceived risk of unwanted severe side-effects of vaccination might
exceed the risk of contracting the disease [171]. This can be seen
with other potentially-lethal infectious diseases. Once those who can
and want to be vaccinated have been done, significant efforts may be
required to encourage further people to become vaccinated. This
would ideally be achieved through a coherent risk-communication
strategy to effectively address the ‘infodemic’ and limit and address
the circulation of inaccurate or misleading information about vac-
cines.
Despite these challenges, it is to be expected that most high-
income countries will finish their first round of vaccination this year,
whereas sufficient vaccination coverage in many low- and middle-
income countries will take considerably longer. Widespread vaccine
nationalism [172], underfunding [173] and patent laws [172] make
the COVAX initiative function sub-optimally. With the current vac-
cines and manufacturing capacities, sufficient coverage for achieving
population immunity in the poorest countries is not expected to hap-
pen before 2023. Thus, the production and global distribution of the
vaccines must be increased massively and rapidly. Potential escape
variants, arising from poorly controlled viral spread in countries
without adequate vaccine access, or waning immunity might necessi-
tate repeated vaccinations, further slowing down the process of
global vaccination.7.2.2. Measures during vaccination rollout
Without careful containment and test-trace-isolate measures, the
population remains vulnerable to COVID-19 during the rollout of vac-
cination programmes. A lack of appropriate caution in the relaxation
of restrictions will lead to high morbidity, with risk of long-COVID,
and mortality. High incidence also favors the emergence of new var-
iants, which can threaten the success of the vaccinations. However,
there is an increasing pressure to ease measures as a larger fraction
of the population has been vaccinated. As can be observed in the
example of Chile, this can have grave consequences [174]. All public
health policy responses to these demands should thus be well consid-
ered.
Immunity certificates or passports to enable the return to normal
life for vaccinated, tested, or recovered people have been considered
or introduced in some regions [175,176]. These have significant ethi-
cal and social issues associated with them. The rules for any use of
such immunity certificates (or similar) will have to be openly and
thoroughly discussed regarding their immunological and ethical con-
sequences, specifically in the light of escape variants and restricted
availability of vaccinations [177]. The distinction between vaccinated
and not (yet) being vaccinated could become another engine of
inequality.
Furthermore, there is a need to reconsider the core metric for
measuring the state of the epidemic: namely, incidence. Incidence
denotes the number of positively-tested COVID-19 cases during a
certain time interval normalized to the population. Many discussions
or rules for implementing or lifting NPIs are guided by incidence
thresholds. However, if more and more people become vaccinated,
the infections will concentrate only in those groups of the population
that are still susceptible, i.e., younger people. In this case, a low inci-
dence would still mean a large number of cases in younger age
groups.
For example, an incidence of 50 per million people per day could
initially mean that 0005% of under 30-year-olds were infected each
day. If we then assume that a third of the population were under
30 years of age and the rest of the population was completely immu-
nized, the same incidence would mean that 0015%, thus three times
more, of under 30-year-olds were infected each day. This incidencePlease cite this article as: E.N. Iftekhar et al., A look into the future of th
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10in the total population would then correspond to a three-fold higher
incidence in those under 30 years old.
Keeping incidence thresholds for tightening and loosening meas-
ures as they are now will therefore put younger people more at risk,
further burdening a group that has been severely affected by the pan-
demic, psychologically [75,79,178], economically [178], and educa-
tionally [178,179]. On the other hand, younger people tend to be less
risk-averse [180] and may be willing to take the risk in exchange for
more individual freedom. Moreover, with increased vaccination
among the elderly, the same incidence means a lower burden on hos-
pitals and lower deaths. This means that current incidence thresholds
would at a later stage correspond to lower risks to healthcare systems
than they do now. A last aspect to consider on the matter of incidence
is that the total incidence remains a rough measure of how well con-
tact tracing can work, even after vaccination. As the feasibility of con-
tact tracing should be a main factor for deciding incidence thresholds
[106], this would be an argument against changing the thresholds.
Nevertheless, this issue will need to be openly discussed with
involvement of all stakeholders.7.3. Digital health systems and operations research to organize mass
vaccinations
The delivery of vaccines and medical accessories involves complex
supply chains, and the fragility of mRNA vaccines, which require a
very good low-temperature cold chain, and may have to be stored at
-20° to -80°Celsius, further complicates planning and logistics [181].
Countries with successful early vaccination programs during the
COVID-19 pandemic, such as Israel and the United Kingdom, have
benefited from an early start of mass vaccination and a steady vaccine
supply:
Israel stands out for its national digital health network and elec-
tronic medical record system, which covers all citizens and can be
accessed by all health management organizations (HMOs) in the
country. The HMOs are independent and compete for members with
a mix of public and private health care services, but a tight regulation
and hierarchical structure in combination with the interconnected
digital network allows the HMOs to implement a national health
operation efficiently. Furthermore, organizational and logistic frame-
works to facilitate the cooperation between government, hospitals
and emergency care providers are well-established, and operations
and health policy research, as well as digital health concepts are used
to improve healthcare procedures [181,182]. A detailed review of
these and other factors which contributed to Israel’s successful vacci-
nation program has been provided by Balicer and Afek [183].
Digital health systems also played a key role in the British vaccina-
tion program. As part of the prior operations research planning, opti-
mal locations of vaccination centers were computationally estimated
in a manner that ensured that every citizen could reach the nearest
center within 10 miles from home [184]. For the supply chain man-
agement, a data analytics company was contracted to create a com-
prehensive supply database for vaccines, accessories and equipment
[185]. The system also integrates information on trained staff for the
vaccinations, non-identifiable patient data, and required materials in
order to help prevent delays. Additionally, it provides up-to-date
progress reports on vaccinations to the NHS to facilitate close moni-
toring. Further elements of the vaccination program that may have
contributed to the early success in the UK have been discussed more
comprehensively in a recent article by Baraniuk [186].
Overall, many of the tools and strategies used in Israel and the UK
in the areas of digital health management and analytics, as well as
operations research, are transferable to other countries. Their deploy-
ment could help to increase the efficiency of vaccine delivery in set-
tings with interdependent supply constraints.e COVID-19 pandemic in Europe: an expert consultation, The Lancet
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There is unequivocal evidence that airborne spread is the domi-
nant route of spread for SARS-CoV-2. Studies on human behaviors,
practices and interactions in choir meetings, slaughterhouses, gyms
and care homes have presented evidence consistent with airborne
spread of SARS-CoV-2 [187]. Long-range transmission between peo-
ple in adjacent rooms but never in each other’s presence has been
documented in quarantine hotels [188]. Healthy building controls,
such as better ventilation and enhanced filtration, are a fundamen-
tal—but often overlooked—part of risk reduction strategies that could
have benefits beyond the current pandemic [189].
Steps should be taken to ensure good ventilation in populated
buildings to mitigate aerosol transmission. Priority should be given
to spaces where ventilation is absent or inadequate, where there are
several people in close proximity or for extended periods of time and
those where infectious persons are more likely to be present. Opti-
mizing natural ventilation by opening windows, increased air
exchange in small rooms with low ceiling heights, scaling up the ven-
tilation in high-occupant-density situations or in locations where
masks are not worn all of the time are suggested [109]. Improving on
this can become a global challenge since significant additional
resources, not directly linked to healthcare budgets, will be needed.
In addition, there has been limited guidance on specific ventilation
and filtration targets. Notwithstanding, improved air quality in con-
fined spaces may not only help to prevent infectious diseases well,
but also to improve well-being and performance, e.g. learning in
school children.
7.5. Waning immunity
The duration of post-infection and vaccine-induced immunity to
COVID-19 might show pronounced individual heterogeneity with
some people not forming efficient immunity at all and others devel-
oping an immune response that might protect from reinfection for
decades. Antibodies against SARS-CoV-2 have been shown at nine
months post-infection [22]. About 95% of subjects retain immune
memory at six months after infection [23-25]. However, reinfections
have also been observed [26-28]. In some individuals reinfections are
possible even just a few months apart [190]. Mechanisms for that as
well as the expected average frequency of reinfection are not well
known. In the case of SARS-CoV-1, humoral immunity was described
to last for up to two to three years whereas antigen-specific T-cells
were detected up to 17 years after infection [191]. It is important to
keep in mind that circulating antibody levels are not necessarily pre-
dictive of T-cell memory or the level of protection. To conclude, wan-
ing immunity is a realistic risk and may necessitate booster shots in
the years to come.
When they occur, reinfections are likely to be less severe because
leftover baseline immunity may shorten the course of infection and
dampen inflammatory responses. Antibody disease enhancement,
analogous to what has been observed in Dengue fever [192], could in
principle occur. However, no evidence so far exists that a reinfection
will lead to more severe symptoms.
7.6. Evolution of SARS-CoV-2
A key unknown in relation to the future of the pandemic is the
ability of the virus to evolve in ways that increase its transmissibility,
its disease severity, or its potential to escape from vaccine induced
immunity. It was thought that the SARS-CoV-2 virus would evolve
more slowly than other RNA viruses as it contains a proofreading
mechanism. However, there has been a clear step change in emer-
gence of constellations of mutations over time, termed “variants of
concern”. These often include specific mutations, for example,
D614G, in the spike protein which enhanced binding to the ACE2Please cite this article as: E.N. Iftekhar et al., A look into the future of the
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10receptors on human cells [193]. This mutation is present in the cur-
rently important VOCs, including Alpha, Beta, Gamma and Delta.
Another mutation, N501Y, involving a substitution of asparagine for
tyrosine as the amino acid at position 501, allows the spike protein to
bind more tightly to the ACE2 receptor, thereby further increasing
the transmissibility of disease [194]. This mutation is also present in
the VOCs Alpha, Beta and Gamma. A third mutation, E484K, reduces
the ability of antibodies generated following vaccination or previous
infection to bind to the spike protein [58,195]. This mutation is pres-
ent in Beta, Gamma and other variants under investigation.
The rollout of vaccination will inevitably change the environment
within which the virus is circulating, creating an evolutionary pres-
sure for further mutations against which existing vaccines may be
less effective. However, many mutations do not increase the fitness
of the virus and may even weaken it, for example by reducing the
ability of the spike protein to bind to the receptor. Thus, much will
depend on whether there is one or a small number of genotypes of
the virus that are optimally configured for transmission. Research
showing convergence of evolution of the spike protein in different
SARS-CoV-2 lineages supports this possibility [196].
This question has been addressed in an analysis of three variants
of concern that have emerged in the pandemic, Alpha, Beta, and
Gamma [197]. Martin and colleagues note that the same mutations
have arisen independently in geographically dispersed populations,
suggesting that, at least in some ways, the evolution of the virus may
be converging on an optimally fit genotype [197]. However, they
note that changes in the environment in which the viruses are being
transmitted may create new opportunities. Variants bearing the
N501Y mutation only began to emerge in the autumn of 2020. Having
reviewed the evolution of the virus so far and of coronaviruses in
other hosts, Martin and colleagues suggest that the most likely sce-
nario is that the virus will evolve in ways that converge on one or
more related “supervariants” with increased transmissibility and
potential for vaccine evasion and they list a set of codons that such
variants might be expected to possess [197]. However, it is not possi-
ble to exclude the situation in which other evolutionary pressures
arise, particularly given the very short time during which this virus
has been circulating in humans, and based on experience with other
viruses.
7.7. How to improve adherence to rules and recommendations
7.7.1. Clearer communication
As the assumed effectiveness of measures is a key predictor of
their protective effects [84], it will remain critically important to
improve scientific communication about them [77]. This is crucial
because specific policies, such as the goal of very low incidence,
require the understanding of complex underlying systems. Politicians
and scientists must speak clearly and truthfully to the public, neither
underplaying nor overplaying the risks associated with the pandemic
or the effectiveness of interventions. Scientists with a public profile
must be extremely mindful of demarcating personal opinion and
interpretation from widely accepted scientific fact. Failure to do so
risks undermining the very public health measures and campaigns
(e.g., vaccination) that scientists are propagating.
The media also has a role to play. It is apparent that coverage has
regularly been influenced by the ideological stance of the media out-
let. In the United States, for example, conservative media outlets
have been highly critical of those warning about the risks of COVID-
19, such as Anthony Fauci, and have promoted conspiracy theories.
Studies at an individual and area level have demonstrated associa-
tions between use of conservative media outlets, such as Fox News,
and belief in conspiracy theories, reduced mask wearing, and lower
reductions in mobility. Another study, using survey data from the
United States and United Kingdom, found that intention to be vacci-
nated was associated with use of broadcast and print media (as wellCOVID-19 pandemic in Europe: an expert consultation, The Lancet
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Kingdom) but not with social media, except in one study that asked
about reliance on it for information, which found an association with
reduced intention [198].
7.7.2. Empowering measures
Adherence to public health measures can only be achieved if peo-
ple have the capacity to do so [199]. This insight is supported by the
fact that especially low adherence has been observed for people in
precarious working conditions [200,201]. We thus need to focus on
making measures socially acceptable, and focus on mental health and
ways to prevent, or at least relieve, social, economic, and psychologi-
cal burdens associated with the pandemic. Helping people to cope
with the situation and strengthening society will ultimately benefit
adherence and ensure the effectiveness of measures [202]. Therefore,
governments need to provide more support of multiple kinds (eco-
nomic aid, more mental healthcare, social help etc.). It is of critical
importance to support people from lower socio-economic back-
grounds. Where possible, stress in parents and thereby in children
should be reduced. This is especially since children have been hit par-
ticularly hard from a mental health perspective [75,79]. It is also vital
to make help accessible to those unfamiliar with the local language,
those unable to apply for help (for instance, due to digital exclusion),
and those unaware of support offers. Support must be directed at
those residing in a country, not merely official citizens of it, to pre-
vent the aggravation of existing inequalities.
7.7.3. Physical, not social, distancing
It should be stressed that restricting the virus does not necessarily
mean restricting social interactions per se. Politicians and scientific
advisors should pursue policies that actively animate community at a
time of loneliness, depression, and anxiety; but in ways that remain
in agreement with the important mission of driving down cases and
fatalities of COVID-19. For instance, investment in urban public
health is very important, from green spaces to small and safe commu-
nity gatherings. For the latter, people should be encouraged to meet
outside in small groups to have social interactions in a physically-dis-
tanced way [203].
7.8. One Health
A One Health approach to disease control considers the interde-
pendence of humans, animals and the environment with interdisci-
plinary thinking and measures [204,205]. Such a holistic multi- and
transdisciplinary approach is required because it is insufficient to
only consider a human health perspective in our interconnected
world. Animal reservoirs most likely play an important role in SARS-
CoV-2 and other viral infections. This is certainly the case with
respect to the origin of viral human pathogens, e.g. in bats, pigs or
chicks [206]. One particularly relevant animal in this regard might be
the bat as a source animal from which viruses can emerge that are
resistant to high temperatures or fever in humans [207]. As SARS-
CoV-2 is now a mainly human-to-human transmitted virus, it is not
entirely clear how much other animals, such as household animals or
farmed animals, play an important role. Several animals that have
been in contact with infected humans have been tested positive for
SARS-CoV-2; minks, dogs, domestic cats, lions and tigers
[124,125,127]. We should monitor the appearance of SARS-CoV-2 in
these and other species closely.
Due to animal reservoirs and because COVID-19 is most likely a
zoonosis [208], human intrusion into the habitat of animals needs to
be considered in the context of pandemics. Overexploitation and hab-
itat destruction significantly increases the risk of newly emerging and
rapidly spreading vectors and diseases [209]. Environmental factors
that are relevant in this context include light pollution and deforesta-
tion, mainly driven by expansion of land for agriculture [210]. From aPlease cite this article as: E.N. Iftekhar et al., A look into the future of th
Regional Health - Europe (2021), https://doi.org/10.1016/j.lanepe.2021.10One Health perspective, it seems essential to reduce global land use
for agriculture.
The connections between animal, human, and environmental
health are complex and require systems thinking. More focus on this
interconnectivity should be placed in education, to foster awareness
of the importance of human actions on such large scales. As we move
further into climate change, a range of serious health issues will
become more common [211-214]. A One Health framework as part of
a planetary and global health perspective to study and manage these
will be helpful [166,215].
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